



SANOFI PASTEUR 
SANOFI PASTEUR 


Potential Controls for an NGS Adventitious Virus
Detection Assay

Outline

- **Overview of Sanofi Pasteur's adventitious virus detection by NGS assay**
- **Controls within the assay**
- **Panel of model viruses**
- **AVDTIG Subgroup A perspective on controls**
- **Summary**

Overview of Sanofi Pasteur's Adventitious Virus Test


- **Designed to test any type of biological material (cell banks, viral seeds, crude harvests, drug substances, drug products)**
 - A whole-genome approach that takes advantage of very deep sequencing



Sample Extraction

- **Two extraction arms that are done in parallel**
 - Based on comparisons between 11 different extraction kits/methods using EBV, RSV, Reo and FeLV as model viruses
 - Enhance the recovery of dsRNA virus
 - Includes an optional low-speed centrifugation to remove cell debris but no nuclease treatment
- **Sequencing library preparation using the Nextera XT**

Current Sample Prep. Approach



Illumina HiSeq1500 Sequencing System

- **The advantage is deep sequencing from a single biological sample**
 - Read length: 150 nt
 - Average # of Read: 400-500 M (paired-end reads)
- **Validated the Illumina HiSeq1500 in 2016**
 - HiSeq 1500 sequencer, Illumina cBot and two computers
 - Network attached storage and remote data storage in a data center




PhyloID Analysis

- **PhyloID™- an automated analysis pipeline for adventitious agent detection with NGS data**
 - Specifically designed for analyzing large sequence datasets for adventitious agent detection
 - A sequence is identified based on its phylogenomic distance to a known set of reference sequences. Both the match strength and the degree of fit can indicate confidence in the assignment
- **Reference genomes are based on RefSeq database**
- **Software and hardware were validated in 2017**



Sanofi Pasteur's Validation Approach





SANOFI PASTEUR 

SANOFI PASTEUR 

Assay Controls and QC Steps


Controls

- **To minimize potential contaminations from the environment**
- **QC steps are important check-points in ensuring performance of the assay**
 - Quantity and integrity of the starting material
 - Sequencing library assessment (size and quantity)
- **Assessment of sequencing reads to remove low quality data**

Flow

- **Personnel flow similar to that of how PCR rooms are setup for a PCR assay**

- Differential airflow to minimize contamination
- All work are done in dedicated BSC



Sample Preparation Controls

- **Each sample are spiked with two types of pseudo-viral particles containing DNA and RNA separately prior to nucleic acid extraction**
 - Designed with sequences that are not expected to be in any samples or the environment
 - System control that monitors the extraction efficiency, cDNA synthesis, library generation and sequencing
 - The number of reads matching the expected DNA and RNA sequences are identified by PhyloID, tracked and use as validity criteria.
- **Each sample is dual-indexed so that each sample can be easily identified and distinguished from previous samples**
 - All testing samples are run in individually lanes or flow cells and are not multiplexed
- **Quantify and sized the nucleic acids using the Agilent BioAnalyzer 2100**
 - cDNA synthesis
 - Sequencing library

Sequencing Control / PhyloID Data Analysis

- **A pre-made dual-indexed sequencing library is added to every sequencing run as a sequencing control**
 - Requires a minimum number of reads to ensure that the test meets the necessary sensitivity
 - Minimum average read quality
- **PhyloID**
 - Adaptor trimming
 - Filters out low quality reads to removes sequencing/PCR errors that might lead to mis-identifications.
 - Helps improve the robustness of the assembly step



SANOPI PASTEUR 

SANOPI PASTEUR 

Panel of Model Viruses

| 1

Model Viruses

- **Model viruses are critical to assessing the performance of an NGS adventitious virus detection assay**
- **NIH published a study in 2014 (Gombold *et al.*) that linked *in vivo* and *in vitro* tests for adventitious virus detection and demonstrated that the *in vivo* tests are not as sensitive**
 - 16 viruses across 9 viral families, representative of potential contaminants that could be introduced during vaccine production
 - Includes human and animal viruses from a variety of families, both RNA and DNA genomes as well as enveloped and non-enveloped viruses
- **This panel can be used to link NGS data to the published *in vivo* and *in vitro* data**
 - Difficult to justify repeating the *in vivo* study because of the ethical consideration and the 3R initiatives to replace, reduce and refine the use of animals.

- Adenovirus 5
- Adenovirus 41
- Simian CMV
- HSV 1 (MacIntyre)
- Simian Virus 40
- BVDV (NY-1)

- Influenza A (A/PR/8/34)
- Measles virus (Edmonston)
- Mumps virus (Enders)
- Bovine Parainfluenzavirus Type 3
- Coxsackievirus A16
- Coxsackievirus B3

- Echovirus 11 (Gregory)
- Rhinovirus 2
- Vesicular Stomatitis Virus (Indiana)
- Rubella virus (M-33)

Summary of NIH study




Systematic evaluation of *in vitro* and *in vivo* adventitious virus assays for the detection of viral contamination of cell banks and biological products^a


James Gombold^a, Stephen Karakasidis^a, Paula Niksa^b, John Podczasy^a, Kitt Neumann^a, James Richardson^c, Nandini Sane^c, Renita Johnson-Leva^c, Valerie Randolph^d, Jerald Sadoff^e, Phillip Minor^f, Alexander Schmidt^g, Paul Duncan^h, Rebecca L. Sheets^{i,*}



In vivo



In vitro




Viral Family	Virus	Strain	Enveloped	Viral Genome	Genome Size (Kb)	Production Cell Line	Cell Line For Titration Assay
Adenoviridae	Adenovirus 5	Adenoid 75	No	dsDNA	36	A549	A549
	Adenovirus 41	N/A	No	dsDNA	34	HEK 293	HEK 293
Flaviviridae	Bovine Viral Diarrhea Virus	NY-1	Yes	ssRNA (+ve)	12.4	BT	BT
Herpesviridae	Herpes Simplex Virus Type 1	MacIntyre	Yes	dsDNA	150	Vero	Vero
	Simian Cytomegalovirus	CS6	Yes	dsDNA	221	MRC-5	MRC-5
Orthomyxoviridae	Influenza A	A/PR/8/34 (H1N1)	Yes	8 ssRNA (-ve)	12.5	MDCK	MDCK
Paramyxoviridae	Mumps	Enders	Yes	ssRNA (-ve)	15.4	Vero	Vero
	Bovine Parainfluenza Type 3	N/A	Yes	ssRNA (-ve)	15.5	Vero	Vero
	Measles	Edmonston	Yes	ssRNA (-ve)	15.9	Vero	Vero
Picornaviridae	Coxsackie A16	N/A	No	ssRNA (+ve)	7.4	Vero	Vero
	Coxsackie B3	N/A	No	ssRNA (+ve)	7.4	LLC-MK2	LLC-MK2
	Echovirus 11	Gregory	No	ssRNA (+ve)	7.4	LLC-MK2	LLC-MK2
	Rhinovirus 2	HGP	No	ssRNA (+ve)	7.1	HeLa	HeLa
Polyomaviridae	Simian Virus 40	Pa-57	No	dsDNA	5.2	Vero	Vero
Rhabdoviridae	Vesicular Stomatitis Virus	Indiana	Yes	ssRNA (-ve)	11.2	Vero	Vero
Togaviridae	Rubella	M-33	Yes	ssRNA (+ve)	9.7	BSC-1	RK-13

Equivalent Viral Stocks

- **Produced a set of equivalent viral stocks**
 - Followed the NIH protocols for virus propagation and titration (as close as possible)
 - Same-sourced cells, media formulations, multiplicity of infection (MOI), infection time, and harvest conditions
 - For some viruses, MOI, infection time and harvest conditions were modified
 - Determined the titer and genome copies for both SP stocks and the NIH stocks
 - **Viruses were provided by the National Institute of Allergy and Infectious Diseases (via Rebecca Sheets)**
- **Used this panel to assess the performance of NGS for adventitious virus detection**

Comparison of Sensitivity between NGS and *In Vivo* Tests



NT = not tested; ND = not detected;
 Viral genome types: dsDNA; ssRNA (-ve); ssRNA (+ve)

★ *In vivo* test show better sensitivity than NGS (and *in vitro* test)

★ Equivalent between *in vivo* and NGS tests

Characterizations of Model Viruses

- **Representation from different viral properties**

- DNA / RNA
- Single-/Double-stranded
- Size
- Segmented/Circular
- Some differences in detection sensitivity have been observed for very similar viruses (but additional work is needed)

- **Titer**

- Limit the number of freeze-thaw

- **Genome copies**

- NGS is a nucleic acid based test

- **Culturing conditions (e.g., serum and host cells) and purification**

- **Sequence information**

- How much data is sufficient?
- What about lab-specific / kit-specific artifacts (do you combine the data or look for the intersect from different labs)?

- **Link to in vivo data as we are considering NGS as a replacement for in vivo assays**




©ULTRA F/Gettyimages

SANOPI PASTEUR 

SANOPI PASTEUR 

Controls (on behalf of Subgroup A of
AVDTIG)

AVDTIG Subgroup A Perspective



viruses



Perspective

Current Perspectives on High-Throughput Sequencing (HTS) for Adventitious Virus Detection: Upstream Sample Processing and Library Preparation

Siemon H. Ng ^{1,*}, Cassandra Braxton ², Marc Eloit ^{3,4}, Szi Fei Feng ⁵, Romain Fragnoud ⁶, Laurent Mallet ⁷, Edward T. Mee ⁸, Sarmitha Sathiamoorthy ^{1,4}, Olivier Vandeputte ⁹ and Arifa S. Khan ¹⁰

- Assessment of RNA and/or DNA integrity
- Spiked in of RNA controls to monitor inhibitions
- qPCR / dPCR as QC steps
- MiSeq Run

Summary

- **QC and controls are important in ensuring consistency of a NGS assay**
 - Different rooms/workflow
 - Controls for extraction, libraries preparation and sequencing
 - Assessing quantity and integrity
- **Need for negative control?**
- **A panel of well-characterized viruses is key to understanding the performance of the assay**

Thank You



SANOFI PASTEUR

